Update on Sanofi Collaboration & License Agreement

RNS Number : 8403S

Oxford Biomedica PLC

19 March 2021

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Oxford Biomedica announces that Sanofi intends to terminate the Collaboration and License Agreement in the field of haemophilia gene therapy

Oxford, UK - 19 March, 2021: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Group"), a leading gene and cell therapy group, announced today that Sanofi has given notice that they intend to terminate the Collaboration and License Agreement for process development and manufacturing of lentiviral vectors to treat haemophilia.

Oxford Biomedica had originally signed the Collaboration and License Agreement with Bioverativ (which was acquired by Sanofi) in February 2018.

The Group expects that the impact on revenue will be negligible over the coming 24 month period.

-Ends-

Enquiries:
Oxford Biomedica plc John Dawson, Chief Executive Officer Stuart Paynter, Chief Financial Officer Catherine Isted, Head of Corporate Development & IR	T: [phone] T: [phone] T: [phone] / E: [e-mail]
Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal	T: [phone]

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a 3 year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people. Further information is available at www.oxb.com

The person who arranged for the release of this announcement on behalf of Oxford Biomedica plc was John Dawson, Chief Executive Officer.

 

END

 

 

MSCJLMFTMTABMLB